Charting a new course in inflammatory and autoimmune disease medicine.
Navigator Medicines is a clinical-stage biotech advancing bispecific antibodies anchored in OX40L inhibition. Our exceptional team is working to bring new hope to people living with complex inflammatory disorders and autoimmune diseases.
We develop bispecific antibodies that simultaneously block OX40L and TNFα, targeting two key drivers of inflammation to deliver better, longer-lasting results for patients.
News
November 20, 2025
Navigator Medicines Completes Last Participant Last Visit (LPLV) in Phase 1b Trial of NAV-240, an OX40L and Anti-TNFα Bispecific Antibody for Autoimmune Diseases
>> READ MORE
September 17, 2025
Navigator Medicines Announces Positive Phase 1a Data from its Program of Potential Best-in-Class Bispecific Antibodies; NAV-240 Poised for Further Development in Inflammatory Disorders and Autoimmune Diseases
>> READ MORE
January 8, 2026
Navigator Medicines Accelerates Anti OX-40L and TNFα Bispecific Antibody Clinical Development Pipeline into Phase 2a and First-in-Human Trials
>> READ MORE